Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last kr11.30 SEK
Change Today -0.05 / -0.44%
Volume 529.6K
As of 11:32 AM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

neurovive pharmaceutical (NVP) Snapshot

Open
kr11.35
Previous Close
kr11.35
Day High
kr11.55
Day Low
kr10.30
52 Week High
09/9/14 - kr80.00
52 Week Low
09/4/15 - kr10.30
Market Cap
347.3M
Average Volume 10 Days
359.9K
EPS TTM
kr-1.75
Shares Outstanding
30.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for NEUROVIVE PHARMACEUTICAL (NVP)

Related News

No related news articles were found.

neurovive pharmaceutical (NVP) Related Businessweek News

No Related Businessweek News Found

neurovive pharmaceutical (NVP) Details

NeuroVive Pharmaceutical AB (publ) engages in the research and development of mitochondrial-protecting pharmaceuticals in Sweden and Hong Kong. Its product portfolio includes CicloMulsion, a drug candidate, which is in Phase III clinical study for cell protection against reperfusion injury during heart attack treatment; NeuroSTAT, a drug candidate that is in Phase IIa clinical study for the treatment of traumatic brain injuries; and NVP019, an intravenous formulation that is in pre-clinical phase for treating myocardial infarct and traumatic brain injury. The company is also developing NVP014 for brain cell protection in stroke; NVP015 for treating mitochondrial diseases in children and drug-induced mitochondrial dysfunction; and NVP018, an antiviral pharmaceutical product to treat hepatitis B and C. It has collaboration agreements with Isomerase Therapeutics and Sihuan Pharmaceutical; and development and commercialization outlicensing agreement with OnCore BioPharma, as well as agreements with Fresenius Kabi and Lyon University Hospital. The company was founded in 2000 and is headquartered in Lund, Sweden.

11 Employees
Last Reported Date: 08/19/15
Founded in 2000

neurovive pharmaceutical (NVP) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

neurovive pharmaceutical (NVP) Key Developments

NeuroVive Pharmaceutical AB Announces Executive Changes

NeuroVive Pharmaceutical AB announced a change in leadership of the company. Effective September 1, 2015, Mikael Brönnegård will no longer serve as Chief Executive Officer. The Board announced that the company's COO Jan Nilsson, who has extensive experience at senior levels within international pharmaceutical companies, will take over as interim CEO. The recruitment process to find a successor has begun and the company’s COO Jan Nilsson will head up the company in the role of interim CEO in the period until a new CEO is appointed by the Board of Directors.

NeuroVive Refocuses CicloMulsion Development

NeuroVive Pharmaceutical AB announced it will not pursue development of CicloMulsion® in the indication of acute myocardial infarction (AMI). The company will now place strategic focus on progressing the research and development activities of CicloMulsion® in acute kidney injury, the development of its other drug candidates as well as accelerating its discovery programs. This decision follows the data presentation from the investigator-initiated Phase III CIRCUS study of CicloMulsion® in patients with a specific type of heart attack known as ST-segment elevation myocardial infarction (STEMI) at the European cardiology meeting in London, UK. The data presented showed that CicloMulsion® had no therapeutic effect on AMI patients undergoing PCI (percutaneous coronary intervention). However, the CIRCUS study confirmed the safety profile of CicloMulsion. NeuroVive remains committed to the Phase II CiPRICS study of CicloMulsion® in pretreatment of acute kidney injury during major surgery, as well as the Phase II CHIC study of NeuroSTAT® in traumatic brain injury. CicloMulsion® is one of several investigational products in clinical and preclinical development.

Neurovive Pharmaceutical Reports Earnings Results for the Second Quarter and Six Months Period from January 1, 2015 to June 30, 2015

Neurovive Pharmaceutical reported earnings results for the second quarter and six months period from January 1, 2015 to June 30, 2015. For the quarter, the company reported net revenues of SEK 2,502,000 against SEK 0 a year ago. Other operating income was SEK 377,000 against SEK 1,128,000 a year ago. Loss before tax was SEK 15,216,000 compared to SEK 13,690,000 a year ago. Diluted loss per share were SEK 0.54 against SEK 0.69 a year ago. For the six months, the company reported net revenues were SEK 2,502,000 against SEK 0 a year ago. Other operating income was SEK 426,000 against SEK 1,171,000 a year ago. Loss before tax was SEK 29,487,000 against SEK 23,567,000 a year ago. Diluted loss per share was SEK 1.02 against SEK 0.50 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVP:SS kr11.30 SEK -0.05

NVP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NVP.
View Industry Companies
 

Industry Analysis

NVP

Industry Average

Valuation NVP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 32.3x
Price/Book 1.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 19.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEUROVIVE PHARMACEUTICAL, please visit www.neurovive.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.